Verification of the Energy Balance of a Passive House by Combining Measurements and Dynamic Simulation

AbstractPassive houses have, at design stage, to fulfill a number of performance criteria. One of them imposes the normalized theoretical heat demand to be limited to 15 kWh/m2, year. In operation, it is very difficult to check, from simple observations or measurements, the real performance of such a house: different energy vectors may be used to meet the space heating as well as the domestic hot water demand, a storage tank may be used and fed by different energy sources (heat pump, direct electricity, solar thermal). The problem is still more complicated if the house is equipped with PV panels which naturally decrease the apparent electrical consumption. In the frame of the IEA Annex 58 project, a passive house was the object of a detailed analysis aiming at estimating the different terms of the energy balance. Some terms were results of direct in situ measurements and unmeasured terms such as solar and internal gains were estimated by dynamic simulation. The combination of measurements and simulation results allowed a reconstruction of a robust energy balance. The paper provides a detailed description of the approach and of each term of the rebuilt energy balance

Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data

Submitted by Repositório Arca ([email protected]) on 2018-07-25T12:28:46Z No. of bitstreams: 2 license.txt: 1748 bytes, checksum: 8a4605be74aa9ea9d79846c1fba20a33 (MD5) Bio-0013.pdf: 852994 bytes, checksum: d75cd666d8542005d0e6016ba864dbf2 (MD5)Approved for entry into archive by Priscila Nascimento ([email protected]) on 2018-10-04T20:06:06Z (GMT) No. of bitstreams: 2 Bio-0013.pdf: 852994 bytes, checksum: d75cd666d8542005d0e6016ba864dbf2 (MD5) license.txt: 1748 bytes, checksum: 8a4605be74aa9ea9d79846c1fba20a33 (MD5)Made available in DSpace on 2018-10-04T20:06:06Z (GMT). No. of bitstreams: 2 Bio-0013.pdf: 852994 bytes, checksum: d75cd666d8542005d0e6016ba864dbf2 (MD5) license.txt: 1748 bytes, checksum: 8a4605be74aa9ea9d79846c1fba20a33 (MD5) Previous issue date: 2012Centers for Disease Control and Prevention. Division of Global Migration and Quarantine. National Center for Emerging and Zoonotic Infectious Diseases. Atlanta, GA, USA. / Centers for Disease Control and Prevention. Division of Vector-Borne Diseases. National Center for Emerging and Zoonotic Infectious Diseases. Fort Collins, CO, USA.World Health Organization. Department of Immunization, Vaccines, and Biologicals. Geneva, Switzerland.Institut Pasteur. Agence de Médecine Préventive. Paris, France.Hospital das Clinicas. Division of Clinical Immunology and Allergy. São Paulo, SP, Brasil.Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública. Rio de Janeiro, Brasil.Sanofipasteur. Global Pharmacovigilance & Epidemiology. Lyon, France. Robert Koch Institute. Berlin, Germany. / Sanofipasteur. Division of Safety Monitoring and Risk Management for Pediatric and Travel Vaccines. Lyon, France.Department of International Health. Center for Immunization Research. Johns Hopkins Bloomberg School of Public Health. Baltimore, MD, USA.Barcelona Centre for International Health Research. Barcelona, Espanha.National Centre of Epidemiology. International Traveller’s Health and Vaccination Centre. Budapest, Hungary.Sanofipasteur. Global Pharmacovigilance and Epidemiology Department. Toronto, Canada.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.Ministry of Health. Epidemiology Direction. Buenos Aires Province, Argentina.Rouen University Hospital. Pharmacovigilance Regional Center of Upper-Normandy. Rouen, Cedex, France.Federal Ministry of Health. Federal Secretariat. Maitama, Abuja, Nigeria.National Institutes of Health. National Institute of Allergy and Infectious Diseases. Division of AIDS. Bethesda, USA.Novartis Vaccines. Cambridge, USA.Harvard School of Public Health. Department of Global Health and Population. Boston, USA